Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 04, 2019 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis

CORAL GABLES, Fla., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
December 18, 2018 11:40 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Definitive Agreement with Endo for Vigabatrin Tablets

CORAL GABLES, Fla., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
December 03, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)

U.S. launch scheduled for early in the first quarter of 2019 Catalyst is well-capitalized and sees no current need for capital infusion CORAL GABLES, Fla., Dec. 03, 2018 (GLOBE NEWSWIRE) --...
November 29, 2018 06:03 ET | Source: Catalyst Pharmaceuticals, Inc.

FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS)

- First evidenced-based medicine approved to treat LEMS - Catalyst Pathways™ designed to facilitate access to Firdapse® and provide dedicated patient support - Launch early in the first quarter of...
November 27, 2018 16:12 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Firdapse® (amifampridine) New Drug Application Continues Under Review

CORAL GABLES, Fla., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals Inc. (Nasdaq:CPRX) today reports that no decision has yet been received from the Food and Drug Administration with...
November 07, 2018 16:19 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX), a biopharmaceutical company...
October 31, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Third Quarter Financial Results and Corporate Update Conference Call and Webcast on Thursday, November 8th, 2018

CORAL GABLES, Fla., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
September 20, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease on September 25-27 in New York CityCantor Fitzgerald Global Healthcare Conference on October 1-3 in New York City CORAL GABLES,...
August 29, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Present at Rodman & Renshaw’s 20th Annual Global Investment Conference

CORAL GABLES, Fla., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...
August 20, 2018 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Appoints Dr. Stanley Iyadurai as Vice President of Clinical Development

CORAL GABLES, Fla., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative...